Literature DB >> 10078607

Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization.

V Endresz1, L Kari, K Berencsi, C Kari, Z Gyulai, C Jeney, S Pincus, U Rodeck, C Méric, S A Plotkin, E Gönczöl.   

Abstract

Plasmids expressing the human cytomegalovirus (HCMV) glycoprotein B (gB) (UL55) or phosphoprotein 65 (pp65) (UL83) were constructed and evaluated for their ability to induce immune responses in mice. The full-length gB as well as a truncated form expressing amino acids 1-680 of gB, and lacking the fragment encoding amino acids 681 907 including the transmembrane domain of gB (gB680) were evaluated. Immunization of mice with plasmids coding for gB or gB680 induced ELISA and neutralizing antibodies, with the highest titres in mice immunized with the gB680 plasmid. Mice immunized with the gB plasmid predominantly produced IgG2a gB-specific antibody, while the gB680 plasmid raised mostly IgG1 anti-gB antibody. Mice immunized with the pp65 plasmid developed pp65-specific cytotoxic T lymphocytes (CTL) and ELISA antibodies. Immunization with a mixture of both gB and pp65 plasmids raised antibodies to both proteins and pp65-specific CTL, indicating a lack of interference between these two plasmids. These results suggest that DNA immunization is a useful approach for vaccination against HCMV disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10078607     DOI: 10.1016/s0264-410x(98)00145-5

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Systemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challenge.

Authors:  Christopher S Morello; Ming Ye; Stephanie Hung; Laura A Kelley; Deborah H Spector
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

2.  Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression.

Authors:  S Pepperl; J Münster; M Mach; J R Harris; B Plachter
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

3.  Molecular, biological, and in vivo characterization of the guinea pig cytomegalovirus (CMV) homologs of the human CMV matrix proteins pp71 (UL82) and pp65 (UL83).

Authors:  Alistair McGregor; Fenyong Liu; Mark R Schleiss
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

Review 4.  Cytomegalovirus vaccine development.

Authors:  M R Schleiss
Journal:  Curr Top Microbiol Immunol       Date:  2008       Impact factor: 4.291

5.  Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus.

Authors:  Zhongde Wang; Corinna La Rosa; Rebecca Maas; Heang Ly; John Brewer; Shahram Mekhoubad; Pirouz Daftarian; Jeff Longmate; William J Britt; Don J Diamond
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

6.  Autoimmune response to U1 small nuclear ribonucleoprotein (U1 snRNP) associated with cytomegalovirus infection.

Authors:  M M Newkirk; W J van Venrooij; G S Marshall
Journal:  Arthritis Res       Date:  2001-04-26

7.  Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex.

Authors:  Felix Wussow; Flavia Chiuppesi; Joy Martinez; John Campo; Erica Johnson; Christin Flechsig; Maegan Newell; Elaine Tran; Jose Ortiz; Corinna La Rosa; Andreas Herrmann; Jeff Longmate; Rana Chakraborty; Peter A Barry; Don J Diamond
Journal:  PLoS Pathog       Date:  2014-11-20       Impact factor: 6.823

8.  Modified vaccinia Ankara expressing EEHV1A glycoprotein B elicits humoral and cell-mediated immune responses in mice.

Authors:  Taylor Pursell; Jennifer L Spencer Clinton; Jie Tan; Rongsheng Peng; Paul D Ling
Journal:  PLoS One       Date:  2022-03-21       Impact factor: 3.240

9.  Clinical Development of a Cytomegalovirus DNA Vaccine: From Product Concept to Pivotal Phase 3 Trial.

Authors:  Larry R Smith; Mary K Wloch; Jennifer A Chaplin; Michele Gerber; Alain P Rolland
Journal:  Vaccines (Basel)       Date:  2013-09-25

Review 10.  A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines.

Authors:  David B Huang; Jashin J Wu; Stephen K Tyring
Journal:  J Infect       Date:  2004-10       Impact factor: 6.072

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.